Jeremy Wolfe, MD
Retina Specialist · Royal Oak, MINPI 1356365514
Payments from drug & device makers
Across 1,151 payments — averaging $3107.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech, Inc.$2.6M
- Regeneron Healthcare Solutions, Inc.$263K
- Genentech USA, Inc.$213K
- Apellis Pharmaceuticals, Inc.$144K
- F. Hoffmann-la Roche AG$118K
- AbbVie$104K
- plus $90K from 15 others
Across 3 payments — averaging $2305.64 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- F. Hoffmann-la Roche AG$7K
What the payments were for
- Consulting fees$239,39830%
- Speaking & faculty fees$495,97261%
- Travel & lodging$53,8877%
- Food & beverage$19,4212%
- Education$2000%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech, Inc. | 308 | $2,644,158 |
| Regeneron Healthcare Solutions, Inc. | 174 | $263,095 |
| Genentech USA, Inc. | 143 | $212,907 |
| Apellis Pharmaceuticals, Inc. | 98 | $143,996 |
| F. Hoffmann-la Roche AG | 162 | $117,710 |
| AbbVie(2 entities) | 129 | $104,147 |
| Alcon | 38 | $40,949 |
| Novartis | 18 | $15,223 |
| Regeneron | 6 | $14,527 |
| Coherus Oncology, Inc. | 5 | $6,305 |
| Roche Products Limited | 1 | $5,880 |
| Alcon Research LLC | 3 | $2,330 |
| Notal Vision, Inc. | 46 | $1,980 |
| Ocular Therapeutix, Inc. | 1 | $1,500 |
| Alimera Sciences, Inc. | 9 | $1,414 |
| Astellas Pharma US Inc | 4 | $116 |
| Biogen | 2 | $50 |
| Hologic Sales And Service, LLC | 1 | $37 |
| Harrow Eye, LLC | 1 | $36 |
| Bausch & Lomb Americas Inc. | 1 | $18 |
| Eyepoint US, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,576,389 in reported general payments places this provider in the 95th percentile of 52 retina specialist providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 123 | $6,173 |
| Ketorolac Tromethamine | 107 | $2,237 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 15 | $1,661 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 24 | $319 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 18 | $228 |
| Brimonidine Tartrate | 16 | $184 |
| Gentamicin Sulfate | 19 | $139 |
Paid to pharmacies, not to this prescriber.
Other retina specialist in Royal Oak
- Tarek HassanRoyal Oak$801K
- Lisa FaiaRoyal Oak$657K
- Antonio CaponeRoyal Oak$179K
- Sandeep RandhawaRoyal Oak$98K
- Kimberly DrenserRoyal Oak$87K
- Michael TreseRoyal Oak$69K
- Adam WeinerRoyal Oak$31K
- Ramon LeeRoyal Oak$19K
- Jong ParkRoyal Oak$12K
- Tianyu LiuRoyal Oak$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.